The combination therapy of insulin and GLP-1 analogs have shown to be highly effective at achieving optimal blood sugar control without an increased risk for hypoglycemia.

In addition, patients on a combination-therapy regimen have been shown to lose weight during treatment.

Both insulin and GLP-1 analogs are currently only available via injection. Oramed is pursuing an oral combination therapy for the management of T2DM, by combining the advantages of ORMD-0801 and ORMD-0901.